Disposition of 278 shares by Gordon Brooks of Eli Lilly subject to Rule 16b-3
| LLY Stock | USD 719.39 5.83 0.80% |
Slightly above 62% of Eli Lilly's investor base is looking to short. The analysis of overall sentiment of trading Eli Lilly and stock suggests that many investors are alarmed at this time. Eli Lilly's investing sentiment can be driven by a variety of factors including economic data, Eli Lilly's earnings reports, geopolitical events, and overall market trends.
Filed transaction by Eli Lilly and Officer: Interim Cfo, Group Vp. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at seekingalpha.com
 |
Eli Lilly Fundamental Analysis
We analyze Eli Lilly's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Eli Lilly is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Eli Lilly Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eli Lilly stock to make a market-neutral strategy. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics with similar companies.
Peers
Eli Lilly Related Equities
| AMGN | Amgen | 2.87 | ||||
| BMY | Bristol Myers | 0.17 | ||||
| JNJ | Johnson Johnson | 0.54 | ||||
| GILD | Gilead Sciences | 0.60 | ||||
| ABBV | AbbVie | 1.42 | ||||
| PFE | Pfizer | 1.82 | ||||
| MRK | Merck | 1.83 |
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.